eGFR Lab Test: Normal vs. Functional Optimal Ranges

What eGFR Actually Measures

Estimated glomerular filtration rate quantifies how many milliliters of blood your kidneys filter per minute, normalized to a standard body surface area of 1.73 m². The test itself does not measure filtration directly. Instead, a laboratory measures serum creatinine (a waste product of muscle metabolism) and plugs that value, along with age and sex, into a validated equation to estimate the rate 1.

The dominant equation in clinical use today is the CKD-EPI 2021 formula, which the National Kidney Foundation and the American Society of Nephrology jointly endorsed after removing the race coefficient from the earlier 2009 version 1. This change affected approximately 3.8 million U.S. adults who were reclassified into a higher CKD stage under the new equation, expanding eligibility for earlier intervention 2.

Creatinine-based eGFR has known blind spots. A person with high muscle mass can produce more creatinine and appear to have worse kidney function than they actually do. The reverse applies to sarcopenic or elderly patients, whose low muscle mass can inflate eGFR artificially. Cystatin C, an alternative biomarker filtered by the kidney, is less affected by muscle mass and can be combined with creatinine for a more precise estimate 3.

Standard Reference Ranges: What Labs Report

Most commercial laboratory panels report eGFR with a single threshold: values at or above 60 mL/min/1.73 m² appear as "normal" or simply ">60." This convention traces back to the 2002 KDOQI guidelines, which defined chronic kidney disease as a sustained eGFR below 60 for three or more months 4. That cutoff was chosen because cardiovascular and mortality risk rises sharply below it.

The KDIGO 2012 guidelines refined this framework into a heat map combining eGFR stages (G1 through G5) with albuminuria categories (A1 through A3), but most standard lab reports still reduce the result to a binary flag 5. A patient with an eGFR of 62 and one with an eGFR of 105 both receive a "normal" result on the same panel. The clinical distance between those two values is enormous.

KDIGO Stage G2 (eGFR 60 to 89) is labeled "mildly decreased" kidney function, yet many labs do not flag it at all. A 2020 analysis in the Journal of the American Society of Nephrology found that adults with eGFR 60 to 89 and no albuminuria had a 1.5-fold higher risk of progressing to Stage 3 CKD within five years compared to those with eGFR above 90 6.

The Endocrine Society's 2020 clinical practice guideline on testosterone therapy specifies that clinicians should assess renal function before initiating treatment, since testosterone cypionate and its metabolites are partially renally cleared 7.

Functional Optimal vs. Conventional Normal

The concept of a "functional optimal" range did not originate in nephrology. It reflects a broader clinical philosophy: lab ranges built on population averages include people with subclinical disease, so the "normal" band is wider (and lower) than the range associated with best health outcomes.

For eGFR, the functional optimal target is 90 to 120 mL/min/1.73 m². This range aligns with KDIGO Stage G1 (eGFR ≥90), which the guidelines define as "normal or high" kidney function 5. The gap between the standard lab flag (60) and the functional target (90) spans 30 mL/min/1.73 m², a zone where filtration is declining but the patient receives no alert on their lab report.

A 2023 meta-analysis published in The Lancet, pooling data from 2.4 million participants across 45 cohorts in the CKD Prognosis Consortium, demonstrated a continuous relationship between lower eGFR and higher all-cause mortality. There was no safe "floor" at 60. Risk began rising at eGFR values below 105, with a hazard ratio of 1.18 (95% CI 1.13 to 1.23) for all-cause mortality at eGFR 75 compared to eGFR 95 8.

"The evidence is clear that eGFR below 90 confers graded risk, even in the absence of albuminuria," wrote Dr. Andrew Levey of Tufts Medical Center, one of the architects of the CKD-EPI equations, in a 2023 editorial in the New England Journal of Medicine 9. This statement supports treating the 60 to 89 range as an early warning zone rather than a clean bill of health.

The distinction between "statistically normal" and "clinically optimal" also matters for medication management. Semaglutide (Ozempic, Wegovy) does not require dose adjustment for mild renal impairment, but the SUSTAIN-6 trial showed that patients with baseline eGFR 30 to 59 experienced a 36% reduction in new or worsening nephropathy with semaglutide versus placebo 10. Knowing whether a patient sits at 95 versus 72 changes the risk calculus.

Why the Gap Between Normal and Optimal Matters for Medication Dosing

Renal function directly governs the dosing, safety, and eligibility of drugs commonly prescribed in hormone therapy, metabolic health, and weight management. A prescriber who relies on the binary "normal" flag may miss dose adjustments that become relevant well above the conventional cutoff of 60.

Metformin is the most familiar example. The FDA updated its labeling in 2016 to allow metformin use in patients with eGFR 30 to 45 at reduced doses, and to contraindicate it below 30 11. But the American Diabetes Association's Standards of Care further recommend monitoring renal function every 3 to 6 months in patients on metformin with eGFR 30 to 60 12. A patient at eGFR 65 receiving no monitoring sits just above the zone where closer surveillance is warranted.

Tirzepatide (Mounjaro, Zepbound) and semaglutide do not require renal dose adjustment per their prescribing information, but GLP-1 receptor agonists slow gastric emptying and can cause dehydration through nausea and reduced fluid intake. In patients with eGFR 60 to 89, that dehydration risk can accelerate filtration decline. The SURPASS-4 trial reported that tirzepatide preserved eGFR better than insulin glargine over 104 weeks, with a between-group difference of 2.2 mL/min/1.73 m² favoring tirzepatide 13.

Testosterone cypionate requires renal awareness as well. While testosterone itself is hepatically metabolized, the polycythemia it can induce increases blood viscosity, raising intraglomerular pressure. The Endocrine Society guideline recommends monitoring hematocrit and renal function in men on TRT, particularly those over 50 or with baseline eGFR below 90 7.

KDIGO's 2024 updated guideline on CKD evaluation and management states: "Clinicians should consider eGFR trajectory, not a single value, when making prescribing decisions. A decline of more than 5 mL/min/1.73 m² per year warrants investigation regardless of absolute level" 14.

How to Support Kidney Function and Raise eGFR

eGFR is not a fixed number. It fluctuates with hydration, protein intake, medication use, blood pressure, and acute illness. A single low result should always be confirmed with a repeat test at 90 days before any clinical action 5.

Blood pressure control is the single most impactful intervention for preserving kidney function. The SPRINT trial (N=9,361) demonstrated that targeting systolic blood pressure below 120 mmHg reduced the composite kidney outcome by 16% compared to a target below 140 mmHg 15. ACE inhibitors and ARBs remain first-line for patients with albuminuria, as they reduce intraglomerular pressure directly.

Hydration affects eGFR acutely. Dehydration concentrates serum creatinine, producing a falsely low eGFR. Patients on GLP-1 agonists who experience nausea should be counseled to maintain fluid intake of at least 2 liters daily, particularly during dose titration.

Protein intake modulates creatinine production. Very high protein diets (above 2.0 g/kg/day) can temporarily raise eGFR through hyperfiltration, which some nephrologists consider a stress response rather than improved function. The KDIGO guideline recommends 0.8 g/kg/day for patients with eGFR below 30 but does not restrict protein in Stage G1 or G2 14.

SGLT2 inhibitors (dapagliflozin, empagliflozin) have strong evidence for kidney protection independent of diabetes status. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal death by 39% (HR 0.61 to 95% CI 0.51 to 0.72) compared to placebo in patients with eGFR 25 to 75 16. The FDA approved dapagliflozin for CKD regardless of diabetes status in 2021.

Exercise influences eGFR through multiple pathways. A 2021 meta-analysis of 12 RCTs (N=796) published in the British Journal of Sports Medicine found that structured aerobic exercise improved eGFR by a mean of 2.16 mL/min/1.73 m² in patients with CKD Stages 3 to 4 17.

Supplements to approach with caution. High-dose creatine supplementation raises serum creatinine and can artificially lower eGFR without reflecting true kidney damage. NSAIDs, even over-the-counter ibuprofen, reduce renal blood flow and can drop eGFR by 10 to 15 points acutely. Patients on TRT or GLP-1 therapy should avoid chronic NSAID use.

When an eGFR Below 90 Requires Action

Not every eGFR below 90 signals kidney disease. Age-related decline is expected. A healthy 70-year-old may have an eGFR of 75 with no albuminuria, stable trajectory, and no clinical concern. Context matters.

The factors that should prompt clinical action at any eGFR below 90 include: albuminuria (urine albumin-to-creatinine ratio above 30 mg/g), a declining trajectory of more than 5 mL/min/1.73 m² per year, concurrent hypertension or diabetes, or planned initiation of renally cleared medications 5.

A single eGFR of 82 in a well-hydrated, muscular 35-year-old warrants a cystatin C confirmation test rather than alarm. A trending decline from 98 to 78 over two years in a 55-year-old on testosterone replacement demands nephrology referral and medication review.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity pharmacotherapy recommends baseline eGFR and repeat testing at 6 and 12 months for all patients initiating GLP-1 receptor agonists, regardless of starting eGFR 18.

Tracking eGFR Over Time: What Matters More Than a Single Number

Trajectory is more informative than any isolated value. A single eGFR is a snapshot. Two or more values separated by at least 90 days reveal the direction and speed of change.

The CKD Prognosis Consortium analysis of 1.1 million participants showed that a 2-year eGFR slope steeper than negative 3 mL/min/1.73 m² per year doubled the risk of kidney failure, even when the absolute eGFR remained above 60 8.

Practical tracking recommendations for patients on hormone therapy or GLP-1 medications:

Test eGFR at baseline before starting any new medication. Repeat at 3 months to establish a two-point trajectory. Then monitor every 6 months if eGFR is above 90 and stable, or every 3 months if eGFR is 60 to 89 or declining. Always order a concurrent urine albumin-to-creatinine ratio, since albuminuria can appear while eGFR remains normal.

Request cystatin C-based eGFR if serum creatinine-based results seem discordant with the clinical picture (high muscle mass, sarcopenia, or recent diet changes). The combined creatinine-cystatin C equation from CKD-EPI 2021 is the most accurate available and reduces misclassification by approximately 15% compared to creatinine alone 3.

Document your results. Lab portals make this simple. A table of eGFR values with dates allows any new clinician to see trajectory within seconds. For patients managing multiple prescriptions (TRT plus metformin plus a GLP-1 agonist), this longitudinal view prevents the common error of treating each lab draw as an isolated event.

Patients with eGFR above 90, no albuminuria, and a stable trajectory over 12 months can extend monitoring to annually, per KDIGO 2024 recommendations 14.